Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
Status:
Terminated
Trial end date:
2018-02-16
Target enrollment:
Participant gender:
Summary
This was a Phase 1, open-label, multicenter, study of checkpoint inhibitor therapy
(tremelimumab ± durvalumab) prior to and following autologous stem cell transplant (ASCT) and
high-dose melphalan in subjects with multiple myeloma who were at a high risk for relapse,
were eligible for ASCT, and had available cryopreserved stem cells. Primary study objectives
were to determine the safety and tolerability of study treatment. Further objectives were to
evaluate the clinical efficacy and biologic activity of the regimen.
Phase:
Phase 1
Details
Lead Sponsor:
Ludwig Institute for Cancer Research
Collaborators:
Cancer Research Institute, New York City MedImmune LLC Multiple Myeloma Research Foundation